文献速递结核与非结核分枝杆菌

辅助性高剂量英夫利西单抗治疗改善重症中枢神经系统结核患者无残疾生存的有效性:一项匹配回顾性队列研究

Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study.
PubMed 文献 · Clin Infect Dis · 2023-01-01

这项匹配回顾性队列研究比较了加用英夫利西单抗(队列A,30例)与仅用抗结核治疗和激素(队列B,60例)的重症中枢神经系统结核成人患者。6个月时队列A严重残疾(16.7% vs 35%)和全因死亡率(6.7% vs 21.7%)均低于队列B,仅英夫利西单抗暴露与无残疾生存正相关(aRR 6.2,95%CI 2.18-17.83,P=.001)。作者认为英夫利西单抗可能是有效且安全的辅助策略,但需3期临床试验确认。

要点

  • 6个月严重残疾:队列A 5/30(16.7%)vs 队列B 21/60(35%)
  • 6个月全因死亡:队列A 2/30(6.7%)vs 队列B 13/60(21.7%)
  • 仅英夫利西单抗暴露与无残疾生存正相关(aRR 6.2,95%CI 2.18-17.83,P=.001)

核心结论

  • 英夫利西单抗可能对 optimal ATT 和激素治疗后未改善的重症残疾中枢神经系统结核患者是有效且安全的辅助策略。
  • 需要足够把握度的3期临床试验来确认这些早期发现。

研究设计与样本

  • 匹配回顾性队列研究,基于英国医学研究理事会(MRC)分级系统和改良Rankin量表(mRS)评分进行匹配。
  • 比较两组中枢神经系统结核成人患者:队列A在2019年3月至2022年7月间接受至少1剂英夫利西单抗(30例),队列B仅接受抗结核治疗和激素(60例)。
  • 主要结局为6个月时无残疾生存(mRS评分≤2)。

主要发现

  • 两队列基线MRC分级和mRS评分相似。
  • 从开始抗结核治疗和激素至启用英夫利西单抗的中位时间为6个月(IQR 3.7-13),神经功能缺损中位时间为4个月(IQR 2-6.2)。
  • 英夫利西单抗指征为症状性结核瘤(20/30;66.7%)、脊髓受累伴轻截瘫(8/30;26.7%)和视交叉蛛网膜炎(3/30;10%),均在充分抗结核治疗和激素下恶化。
  • 6个月严重残疾:队列A 5/30(16.7%)vs 队列B 21/60(35%)。
  • 6个月全因死亡:队列A 2/30(6.7%)vs 队列B 13/60(21.7%)。

临床怎么用

  • 作者认为英夫利西单抗可能是对充分抗结核治疗和激素后未改善的重症残疾中枢神经系统结核患者的有效且安全的辅助策略。
  • 作者建议需要足够把握度的3期临床试验来确认这些早期发现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few treatment options exist for patients with severe central nervous system (CNS) tuberculosis (TB) worsening due to inflammatory lesions, despite optimal antitubercular therapy (ATT) and steroids. Data regarding the efficacy and safety of infliximab in these patients are sparse. METHODS: We performed a matched retrospective cohort study based on Medical Research Council (MRC) grading system and modified Rankin Scale (mRS) scores comparing 2 groups of adults with CNS TB. Cohort A received at least 1 dose of infliximab after optimal ATT and steroids between March 2019 and July 2022. Cohort B received only ATT and steroids. Disability-free survival (mRS score ≤2) at 6 months was the primary outcome. RESULTS: Baseline MRC grades and mRS scores were similar between the cohorts. Median duration before initiation of infliximab therapy from start of ATT and steroids was 6 (IQR: 3.7-13) months and for neurological deficits was 4 (IQR: 2-6.2) months. Indications for infliximab were symptomatic tuberculomas (20/30; 66.7%), spinal cord involvement with paraparesis (8/30; 26.7%), and optochiasmatic arachnoiditis (3/30; 10%), worsening despite adequate ATT and steroids. Severe disability (5/30 [16.7%] and 21/60 [35%]) and all-cause mortality (2/30 [6.7%] and 13/60 [21.7%]) at 6 months were lower in cohort A versus cohort B, respectively. In the combined study population, only exposure to infliximab was positively associated (aRR: 6.2; 95% CI: 2.18-17.83; P = .001) with disability-free survival at 6 months. There were no clear infliximab-related side effects noted. CONCLUSIONS: Infliximab may be an effective and safe adjunctive strategy among severely disabled patients with CNS TB not improving despite optimal ATT and steroids. Adequately powered phase 3 clinical trials are required to confirm these early findings.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Manesh A, Gautam P, Kumar D SS, et al. Effectiveness of Adjunctive High-Dose Infliximab Therapy to Improve Disability-Free Survival Among Patients With Severe Central Nervous System Tuberculosis: A Matched Retrospective Cohort Study. Clin Infect Dis. 2023. PMID: 37405816. doi:10.1093/cid/ciad401

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。